Sandro A. Pignata

Naples, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 355 publications

Study protocol on quality of life and erectile function recovery in unfavorable intermediate-risk prostate cancer: REDI-CaP trial.

Study protocol on quality of life and erectile function recovery in unfavorable intermediate-risk prostate cancer: REDI-CaP trial.

Journal: Future oncology (London, England)

Published: August 27, 2026

Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond.

Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: May 06, 2026

Inavolisib for PIK3CA-mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial.

Inavolisib for PIK3CA-mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: April 27, 2026

Real-World Analysis of Metastatic Renal Cell Carcinoma Patients Treated with Pembrolizumab Plus Axitinib: Evidence from the Campania Oncology Network.

Real-World Analysis of Metastatic Renal Cell Carcinoma Patients Treated with Pembrolizumab Plus Axitinib: Evidence from the Campania Oncology Network.

Journal: Current oncology (Toronto, Ont.)

Published: April 22, 2026

The TRUST trial in ovarian cancer: a missed opportunity or a turning point? The position of the Italian MITO group.

The TRUST trial in ovarian cancer: a missed opportunity or a turning point? The position of the Italian MITO group.

Journal: Frontiers in oncology

Published: April 11, 2026

Somatic BRCA1 and BRCA2 detection in homologous recombination deficiency testing: concordance of four sequencing workflows with the Myriad myChoice companion diagnostic.

Somatic BRCA1 and BRCA2 detection in homologous recombination deficiency testing: concordance of four sequencing workflows with the Myriad myChoice companion diagnostic.

Journal: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society

Published: March 17, 2026

Establishment of the Campania Oncology Network (Rete Oncologica Campana, ROC): a paradigm shift in oncological care and real world research in the Campania region.

Establishment of the Campania Oncology Network (Rete Oncologica Campana, ROC): a paradigm shift in oncological care and real world research in the Campania region.

Journal: ESMO real world data and digital oncology

Published: February 06, 2026

Physical Activity, Nutritional Status, and Health-Related Quality of Life in Newly Diagnosed Cancer Patients: Evidence from the NUTRISCREEN Project.

Physical Activity, Nutritional Status, and Health-Related Quality of Life in Newly Diagnosed Cancer Patients: Evidence from the NUTRISCREEN Project.

Journal: Nutrients

Published: February 02, 2026

Clinical and molecular heterogeneity in advanced-stage POLE-mutated endometrial carcinoma: a focus on aggressive subsets and co-mutations.

Clinical and molecular heterogeneity in advanced-stage POLE-mutated endometrial carcinoma: a focus on aggressive subsets and co-mutations.

Journal: Frontiers in oncology

Published: January 31, 2026

Cancer in migrant populations: evidence from a regional oncology network.

Cancer in migrant populations: evidence from a regional oncology network.

Journal: BMC public health

Published: January 23, 2026

Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.

Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775.

Journal: Journal for immunotherapy of cancer

Published: January 20, 2026

Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC).

Real-world outcomes of second-line pembrolizumab in urothelial carcinoma: a multicenter analysis from the Campania Oncological Network (ROC).

Journal: BMC cancer

Published: January 20, 2026

Showing 1-12 of 355

Last Updated: 09/26/2026